Physician profile
Anna Damian
NPI 1861444655
$882.53
in general payments reported to CMS, 2019-2025
13 companies · $16.24 in 2025
The $16.24 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.23 · 2020: $189 · 2021: $247 · 2022: $190 · 2023: $114 · 2024: $53.41 · 2025: $16.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $183.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $300.03 | 2019-2024 | |
| Novo Nordisk INC | $230.87 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Boston Scientific Corporation | $123.23 | 2021 | |
| Merck Sharp & Dohme LLC | $43.08 | 2021-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $37.95 | 2022 | |
| Abbott Laboratories | $33.90 | 2022 | |
| Genentech USA, INC. | $28.84 | 2020-2021 | |
| Abbvie INC. | $22.34 | 2023 | Vraylar |
| Exact Sciences Corporation | $18.40 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.06 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.99 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.84 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Damian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.